A stroke occurs when the blood supply to part of the brain is interrupted or reduced, causing brain cells to die within minutes due to a lack of oxygen and nutrients. Strokes can result from a blocked artery (ischemic stroke) or a burst blood vessel (hemorrhagic stroke), with quick medical intervention being crucial to minimize brain damage. In the stroke market, advanced clot retrieval devices, such as stent retrievers and aspiration catheters, play a vital role in ischemic stroke treatment. These devices quickly and effectively remove blood clots from brain arteries, restoring blood flow, reducing disability, and enhancing recovery rates when used promptly after stroke onset.
Global Stroke Market was valued at 30,308,643.28 thousand in 2022 and is expected to reach USD 52,232,195.85 thousand by 2030 with a CAGR of 7.50% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-stroke-market
Below are the Top Stroke Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Bristol-Myers Squibb Company
|
Bristol-Myers Squibb is a global biopharmaceutical company known for its innovative medicines, including those for cardiovascular conditions. In the stroke market, it focuses on developing and marketing anticoagulant therapies such as Eliquis (apixaban), which helps prevent stroke in patients with atrial fibrillation by reducing the risk of blood clots forming.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2023, Bristol Myers Squibb (NYSE: BMY) in partnership with Janssen Pharmaceuticals, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson (Janssen), announced that all three potential indications for milvexian, an investigational oral factor XIa (FXIa) inhibitorhas now received fast track designation from the U.S. Food and Drug Administration (FDA). The names include all three trials seeking indications in the Phase 3 Librexiadevelopment program (Librexia STROKE, Librexia ACS, and Librexia AF), all dosed patients. The Librexia program is unparalleled as a comprehensive clinical development program for FXIa, providing extensive data from nearly 50,000 patients. This opens the door to a whole new range of currently neglected patients due to the risk of bleeding.
|
|
2.
|
Boehringer Ingelheim International GmbH
|
Boehringer Ingelheim contributes to the stroke market through its anticoagulant medication, Pradaxa (dabigatran). Pradaxa is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, thus playing a crucial role in stroke prevention.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
Boehringer Ingelheim is a leading pharmaceutical company that has a strong focus on addressing stroke, a major global health issue. The company has launched several initiatives to raise awareness about stroke and improve acute care for stroke patients. This includes the Angels Initiative, a program that works to enhance stroke treatment and care across healthcare systems. Boehringer Ingelheim has also partnered with the government of Maharashtra, India to strengthen stroke care in the state. Additionally, the company's stroke awareness campaign in India has set a Guinness World Record for the most people participating in a stroke awareness lesson.
|
|
3.
|
F. Hoffmann-La Roche Ltd.
|
Roche is a major player in the healthcare industry, known for its diagnostics and pharmaceuticals. In the stroke market, Roche focuses on developing advanced diagnostic tools and therapeutic solutions that aid in the early detection and effective management of stroke, contributing to improved patient outcomes.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In July 2023, Roche announced a new partnership with Alnylam to develop and commercialize zilebesir, an investigational RNAi therapy currently in Phase 2 for treating high blood pressure. This collaboration combines Alnylam's proven experience in RNAi therapy with Roche's global commercial reach, commitment to innovation, and desire to change the landscape for patients with severe cardiovascular disease.
|
|
4.
|
DAIICHI SANKYO COMPANY, LIMITED
|
Daiichi Sankyo has made significant strides in the stroke market with its development of novel anticoagulants. One of its key products, Edoxaban (Savaysa/Lixiana), is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, highlighting its commitment to stroke prevention.
|
|
Americas, Asia-Pacific, and Europe
|
In September 2020, Daiichi Sankyo Company Limited announced that it had submitted a supplemental application in Japan for the extended approval of the anticoagulant edoxaban (edoxaban benzoate hydrate) in elderly patients with nonvalvular regurgitation and severe bleeding risk. This application is based on the results of a Japanese Phase 3 clinical trial (ELDERCARE-AF trial) in 984 patients with non-valvular atrial fibrillation who are at least 80 years old and have a high risk of bleeding and are not suitable for other available anticoagulant therapies. Daiichi Sankyo plans to contribute to treating elderly patients with non-valvular atrial fibrillation by offering a new treatment option.
|
|
5.
|
Sanofi
|
Sanofi a range of treatments for various medical conditions, including stroke. In the stroke market, Sanofi is involved in the development and distribution of anticoagulant and antiplatelet therapies, such as Plavix (clopidogrel), which is used to prevent stroke and other cardiovascular events by inhibiting blood clot formation.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2023, Sanofi's investigational oral Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for treating multiple sclerosis (MS) has shown significant effects on key immune mediators that can promote disease progression in the central nervous system. Researchers measured proteomic changes in the cerebrospinal fluid of MS patients treated with tolebrutinib compared to patients who received no or the B-cell-depleting treatment of ocrelizumab. These findings come from collaborative research and development with the National Institute of Neurological Disorders and Stroke (NINDS) and will be presented at the 2023 Forum of the American Committee on Treatment and Research in Multiple Sclerosis (ACTRIMS).
|
Conclusion
In the stroke market, leading pharmaceutical companies are making significant advancements to improve patient outcomes and prevent stroke occurrences. Bristol-Myers Squibb, Boehringer Ingelheim, F. Hoffmann-La Roche, Daiichi Sankyo, and Sanofi are all contributing with innovative anticoagulants, diagnostic tools, and therapeutic solutions. These companies are focused on reducing the risk of stroke through medications such as Eliquis, Pradaxa, and Edoxaban, as well as by providing advanced diagnostics for early detection. Their efforts are crucial in managing stroke risks and enhancing the quality of life for patients worldwide.
